Literature DB >> 32833503

Circ_0011292 Enhances Paclitaxel Resistance in Non-Small Cell Lung Cancer by Regulating miR-379-5p/TRIM65 Axis.

Chunhong Guo1, Hailiang Wang1, Housen Jiang2, Liang Qiao3, Xinli Wang1.   

Abstract

Background: Non-small cell lung cancer (NSCLC) is the most prevalent cancer in the world. Chemotherapy resistance is a major obstacle to NSCLC therapy. This study explored the role and molecular mechanism of circular RNA 0011292 (circ_0011292) in tumorigenesis and chemoresistance of NSCLC.
Methods: The levels of circ_0011292, miR-379-5p, and tripartite motif-containing protein 65 (TRIM65) were measured by quantitative real-time polymerase chain reaction or Western blot assay. Cell proliferation was assessed by Cell Counting Kit-8 (CCK-8) assay. Cell apoptosis was monitored by flow cytometry. Cell migration and invasion were detected by transwell assay. The levels of apoptosis-related and epithelial-mesenchymal transition-related proteins were examined by Western blot. The half-inhibition concentration (IC50) of paclitaxel (PTX) was evaluated by CCK-8 assay. Xenograft model was established to analyze the effect of circ_0011292 on PTX resistance of NSCLC in vivo. The interaction among circ_0011292, miR-379-5p, and TRIM65 was verified by dual-luciferase reporter assay and RNA immunoprecipitation assay.
Results: Circ_0011292 and TRIM65 were upregulated, while miR-379-5p was downregulated in NSCLC tissues and cells. Circ_0011292 knockdown hindered NSCLC progression and enhanced PTX sensitivity of NSCLC. Circ_0011292 silencing reduced PTX resistance in vivo. Besides, miR-379-5p potentiated PTX sensitivity by targeting TRIM65. Also, circ_0011292 increased PTX resistance by sponging miR-379-5p.
Conclusion: Circ_0011292 facilitated tumorigenesis and PTX resistance in NSCLC by regulating the miR-379-5p/TRIM65 axis, suggesting that circ_0011292 was a promising therapeutic target for NSCLC chemotherapy.

Entities:  

Keywords:  TRIM65; circ_0011292; miR-379-5p; non-small cell lung cancer; paclitaxel

Mesh:

Substances:

Year:  2020        PMID: 32833503     DOI: 10.1089/cbr.2019.3546

Source DB:  PubMed          Journal:  Cancer Biother Radiopharm        ISSN: 1084-9785            Impact factor:   3.099


  10 in total

Review 1.  Advances in the Study of CircRNAs in Tumor Drug Resistance.

Authors:  Song Wang; Long Qian; Tingting Cao; Li Xu; Yan Jin; Hao Hu; Qingsheng Fu; Qian Li; Ye Wang; Jiawei Wang; Yabin Xia; Xiaoxu Huang
Journal:  Front Oncol       Date:  2022-05-09       Impact factor: 5.738

Review 2.  Circular RNAs: new biomarkers of chemoresistance in cancer.

Authors:  Jiaqi Wang; Yi Zhang; Lianyu Liu; Ting Yang; Jun Song
Journal:  Cancer Biol Med       Date:  2021-03-19       Impact factor: 4.248

3.  The Involvement of the hsa_circ_0088494-miR-876-3p-CTNNB1/CCND1 Axis in Carcinogenesis and Progression of Papillary Thyroid Carcinoma.

Authors:  Weiyang Lou; Bisha Ding; Jiannan Wang; Yongfang Xu
Journal:  Front Cell Dev Biol       Date:  2020-12-09

Review 4.  The Role of Circular RNAs in the Drug Resistance of Cancers.

Authors:  Xin-Yuan Liu; Qi Zhang; Jing Guo; Peng Zhang; Hua Liu; Zi-Bin Tian; Cui-Ping Zhang; Xiao-Yu Li
Journal:  Front Oncol       Date:  2022-01-05       Impact factor: 6.244

5.  Blocking hsa_circ_0074027 suppressed non-small cell lung cancer chemoresistance via the miR-379-5p/IGF1 axis.

Authors:  Shizhen Zheng; Chao Wang; Hao Yan; Yuejun Du
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

6.  Circ_0020123 enhances the cisplatin resistance in non-small cell lung cancer cells partly by sponging miR-140-3p to regulate homeobox B5 (HOXB5).

Authors:  Dong Wei; Jing Zeng; Feng Rong; Yasheng Xu; Rong Wei; Can Zou
Journal:  Bioengineered       Date:  2022-03       Impact factor: 3.269

7.  Circ_0011292 knockdown mitigates progression and drug resistance in PTX-resistant non-small-cell lung cancer cells by regulating miR-433-3p/CHEK1 axis.

Authors:  Ming Jin; Fengping Zhang; Qiubo Li; Ruiqi Xu; Ying Liu; Yong Zhang
Journal:  Thorac Cancer       Date:  2022-03-29       Impact factor: 3.223

8.  Circular RNA hsa_circ_0011298 enhances Taxol resistance of non-small cell lung cancer by regulating miR-486-3p/CRABP2 axis.

Authors:  Yihong Wu; Jieyun Xie; Han Wang; Shufang Hou; Jiuhuan Feng
Journal:  J Clin Lab Anal       Date:  2022-04-08       Impact factor: 3.124

Review 9.  Role of circular RNAs in the diagnosis, regulation of drug resistance and prognosis of lung cancer.

Authors:  Chengpeng Sang; Dingyu Rao; Caixia Wu; Yao Xia; Maoyan Si; Zhixian Tang
Journal:  Oncol Lett       Date:  2022-07-07       Impact factor: 3.111

Review 10.  Circular RNAs in Lung Cancer: Recent Advances and Future Perspectives.

Authors:  Huan-Huan Chen; Tie-Ning Zhang; Qi-Jun Wu; Xin-Mei Huang; Yu-Hong Zhao
Journal:  Front Oncol       Date:  2021-07-06       Impact factor: 6.244

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.